Combination chemotherapy and radiation for palliation of hepatocellular carcinoma

V. Dhir, Santhi Swaroop Vege, K. M. Mohandas, K. A. Dinshaw, D. C. Desai, A. Nagral, V. Sharma, P. Jagannath, L. J. Desouza

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Twenty seven patients with hepatocellular carcinoma were treated by sequential methotrexate (75 mg/m2) and 5-fluorouracil (5-FU) (750 mg/m2) on day 1 followed on days 8-36 by external beam radiotherapy (total dose 30 cGy). The response was assessed by liver size on clinical examination. One patient had complete response, and six patients had partial response. The overall response to the treatment was 25.9%. More than a 50% reduction in serum alfafetoprotein level was noted in 66.6% patients. Seventy-one percent of patients had palliation of pain following therapy. The median survival of responders was 11 months and of nonresponders, 2 months. Radiation was discontinued in two patients who developed radiation hepatitis. Additional trials with different dosages and schedules are needed to fully evaluate this form of therapy.

Original languageEnglish (US)
Pages (from-to)304-307
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume15
Issue number4
StatePublished - 1992
Externally publishedYes

Fingerprint

Combination Drug Therapy
Hepatocellular Carcinoma
Radiation
Methotrexate
Fluorouracil
Hepatitis
Appointments and Schedules
Radiotherapy
Therapeutics
Pain
Survival
Liver
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dhir, V., Vege, S. S., Mohandas, K. M., Dinshaw, K. A., Desai, D. C., Nagral, A., ... Desouza, L. J. (1992). Combination chemotherapy and radiation for palliation of hepatocellular carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 15(4), 304-307.

Combination chemotherapy and radiation for palliation of hepatocellular carcinoma. / Dhir, V.; Vege, Santhi Swaroop; Mohandas, K. M.; Dinshaw, K. A.; Desai, D. C.; Nagral, A.; Sharma, V.; Jagannath, P.; Desouza, L. J.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 15, No. 4, 1992, p. 304-307.

Research output: Contribution to journalArticle

Dhir, V, Vege, SS, Mohandas, KM, Dinshaw, KA, Desai, DC, Nagral, A, Sharma, V, Jagannath, P & Desouza, LJ 1992, 'Combination chemotherapy and radiation for palliation of hepatocellular carcinoma', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 15, no. 4, pp. 304-307.
Dhir, V. ; Vege, Santhi Swaroop ; Mohandas, K. M. ; Dinshaw, K. A. ; Desai, D. C. ; Nagral, A. ; Sharma, V. ; Jagannath, P. ; Desouza, L. J. / Combination chemotherapy and radiation for palliation of hepatocellular carcinoma. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1992 ; Vol. 15, No. 4. pp. 304-307.
@article{18a90a70e84846c5bf2ae8058bf3395e,
title = "Combination chemotherapy and radiation for palliation of hepatocellular carcinoma",
abstract = "Twenty seven patients with hepatocellular carcinoma were treated by sequential methotrexate (75 mg/m2) and 5-fluorouracil (5-FU) (750 mg/m2) on day 1 followed on days 8-36 by external beam radiotherapy (total dose 30 cGy). The response was assessed by liver size on clinical examination. One patient had complete response, and six patients had partial response. The overall response to the treatment was 25.9{\%}. More than a 50{\%} reduction in serum alfafetoprotein level was noted in 66.6{\%} patients. Seventy-one percent of patients had palliation of pain following therapy. The median survival of responders was 11 months and of nonresponders, 2 months. Radiation was discontinued in two patients who developed radiation hepatitis. Additional trials with different dosages and schedules are needed to fully evaluate this form of therapy.",
author = "V. Dhir and Vege, {Santhi Swaroop} and Mohandas, {K. M.} and Dinshaw, {K. A.} and Desai, {D. C.} and A. Nagral and V. Sharma and P. Jagannath and Desouza, {L. J.}",
year = "1992",
language = "English (US)",
volume = "15",
pages = "304--307",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Combination chemotherapy and radiation for palliation of hepatocellular carcinoma

AU - Dhir, V.

AU - Vege, Santhi Swaroop

AU - Mohandas, K. M.

AU - Dinshaw, K. A.

AU - Desai, D. C.

AU - Nagral, A.

AU - Sharma, V.

AU - Jagannath, P.

AU - Desouza, L. J.

PY - 1992

Y1 - 1992

N2 - Twenty seven patients with hepatocellular carcinoma were treated by sequential methotrexate (75 mg/m2) and 5-fluorouracil (5-FU) (750 mg/m2) on day 1 followed on days 8-36 by external beam radiotherapy (total dose 30 cGy). The response was assessed by liver size on clinical examination. One patient had complete response, and six patients had partial response. The overall response to the treatment was 25.9%. More than a 50% reduction in serum alfafetoprotein level was noted in 66.6% patients. Seventy-one percent of patients had palliation of pain following therapy. The median survival of responders was 11 months and of nonresponders, 2 months. Radiation was discontinued in two patients who developed radiation hepatitis. Additional trials with different dosages and schedules are needed to fully evaluate this form of therapy.

AB - Twenty seven patients with hepatocellular carcinoma were treated by sequential methotrexate (75 mg/m2) and 5-fluorouracil (5-FU) (750 mg/m2) on day 1 followed on days 8-36 by external beam radiotherapy (total dose 30 cGy). The response was assessed by liver size on clinical examination. One patient had complete response, and six patients had partial response. The overall response to the treatment was 25.9%. More than a 50% reduction in serum alfafetoprotein level was noted in 66.6% patients. Seventy-one percent of patients had palliation of pain following therapy. The median survival of responders was 11 months and of nonresponders, 2 months. Radiation was discontinued in two patients who developed radiation hepatitis. Additional trials with different dosages and schedules are needed to fully evaluate this form of therapy.

UR - http://www.scopus.com/inward/record.url?scp=0026637686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026637686&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 304

EP - 307

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 4

ER -